2023年6月8日

2023年6月8日,埃裏卡·漢密爾頓博士討論了輔助的療效和安全性abemaciclib +內分泌治療激素受體陽性患者,her2陰性,高危早期乳腺癌根據年齡。埃裏卡·漢密爾頓MD、導演、乳腺癌和婦科癌症研究,莎拉大炮研究所,討論了輔助的療效和安全性abemaciclib (Verzenio) +內分泌治療(ET)患者激素受體(HR)陽性,her2陰性,高危早期乳腺癌根據年齡。很大一部分的新診斷乳腺癌患者65歲以上。這些病人體驗更高的並發症發生率和發展與癌症治療的毒性的風險,需要具體指導治療管理在這個高風險的子群。四年年齡組分析階段的結果3 monarchE試驗(NCT03155997)進行評估該方案的好處病人65歲或更老。在monarchE,病人被隨機分配接受內分泌治療10年有或沒有輔助abemaciclib 2年。在這個分析中,患者分組根據他們是否小於65或65歲以上。療效和安全性結果與實驗方案對每個小組進行評估。結果表明,老年患者類似的好處來自輔助abemaciclib年輕同行,表明他們的癌症不懶惰。此外,患者臨床上有意義的減少維護的風險患浸潤性無病生存期(台灣)和遙遠的無複發生存期(DRFS)事件與實驗方案與年齡無關。 At approximately 4 years of follow-up, the iDFS rate in the older age group was 82.0% with adjuvant abemaciclib vs 76.8% with endocrine therapy alone. This resulted in an absolute difference of 5.2% (HR, 0.767; 95% CI, 0.556-1.059). In patients younger than 65, these rates were 86.5% and 79.8%, respectively. The absolute difference in this population was 6.7% (HR, 0.646; 95% CI, 0.554-0.753). Regarding safety, most older patients did not experience an increase in the incidence of all-grade adverse effects (AEs) vs younger patients. Notably, neutropenia, interstitial lung disease, and venous thromboembolism occurred at similar rates in both groups. However, older patients had a 5% higher likelihood of experiencing a serious (grade 3 or greater) AEsvs younger patients. For example, AEs such as diarrhea and fatigue were less common overall but occurred more frequently at higher severity in the elderly population. Accordingly, treatment-related dose discontinuations and reductions were more frequent in the elderly population. The rate of drug discontinuation was 38% in patients older than 65, and 15% in those younger than 65. Overall, the agent still showed comparable tolerability in both age groups. Disclosures: Dr Hamilton reported serving as a consultant or in an advisory role for AstraZeneca, Daiichi Sankyo, Ellipses Pharm, Genentech/Roche, Greenwich LifeSciences, ITeos Therapeutics, Janssen, Lilly, Loxo, Mersana, Novartis, Olema Pharmaceuticals, Orum Therapeutics, Pfizer, Relay Therapeutics, Seagen, Stemline Therapeutics, Theratechnologies, Tubulis GmbH, Verascity Science; she received institutional research funding from Abbvie, Accutar Biotech, Acerta Pharma, ADC Therapeutics, Akeso Biopharma, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond Therapeutics, Bliss Biopharmaceutical, Boehringer Ingelheim, Cascadian Therapeutics, Clovis Oncology , Compugen, Context Therapeutics, Cullinan Oncology, Curis, CytomX Therapeutics, Daiichi Sankyo, Dana Farber Cancer Hospital, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Ellipses Pharma, Elucida Oncology, EMD Serono, Fujifilm, G1 Therapeutics, Genentech/Roche, H3 Biomedicine, Harpoon, Hutchison MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, InventisBio, Jacobio, K-Group Beta, Karyopharm Therapeutics, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo, Lycera, MabSpace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis , Nucana, Olema Pharmaceuticals, OncoMed, Onconova Therapeutics, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr, Plexxikon, Prelude Therapeutics, ProfoundBio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicines, Rgenix, Seagen, Sermonix Pharmaceuticals, Shattuck Labs, Stem CentRx, Sutro Biopharma, Syndax, Syros Pharmaceuticals, Taiho Pharmaceutical, TapImmune Inc, Tesaro, Tolmar, Torque, Treadwell Therapeutics, Verastem, Zenith Epigenetics, and Zymeworks. Related Videos